For a decade, the IPF Summit has been the go-to, intimate, discussion-based venue for stakeholders across the pulmonary fibrosis landscape, and this year’s conversation is more important than ever.
IPF has entered a new era that is much more complicated than before, as a wave of good Phase III readouts from Boehringer Ingelheim and United Therapeutics changes the treatment landscape.
With different therapies emerging, shifting standards of care, and rising demand to demonstrate differentiated value, the challenge has shifted from determining whether effective treatments can be developed to how to do so better, more quickly, and with greater impact for patients.
The 10th IPF Summit is the only end-to-end, industry-led event dedicated to addressing this issue head-on.
Over 150 experts in discovery, translational science, and clinical development from top companies, including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, Contineum Therapeutics, Mediar Therapeutics, and others, will be present.
Providing a uniquely integrated view of the challenges and possibilities shaping the next decade of IPF drug development, from innovative biology and biomarker-driven techniques to next-generation trial design and combination approaches, this is where professionals come to agree on what success looks like now.
If you want to stay competitive in a quickly changing sector, this is the room you should be in.
Explore the full event guide
- Gain insight from 40+ expert speakers.
- Brand-new ILD and PPF Focus Day focused on ILDs, PPF, and the complexities of drug development
- Brand-new Investor Panel with insights into creating conviction early on to generate true investor confidence, and more
- Structured dual-tracked content days covering emerging biology and early translation, as well as late translation and clinical, to address the most urgent difficulties at that stage of development
About 10th IPF Summit
For a decade, the IPF Summit has been the go-to intimate discussion-based forum uniting stakeholders across the pulmonary fibrosis landscape, and this year, the conversation has never been more critical.
As a wave of positive Phase III readouts from Boehringer Ingelheim and United Therapeutics reshapes the treatment landscape, IPF has entered a new era, even more complex than before.
With multiple therapies emerging, evolving standards of care, and increasing pressure to demonstrate differentiated value, the question is no longer if we can develop effective treatments, but how to do so smarter, faster, and with greater impact for patients.
The 10th IPF Summit is the only end-to-end, industry-led meeting designed to tackle this head-on.
Bringing together over 150 experts across discovery, translational science, and clinical development, from leading companies including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, Contineum Therapeutics, Mediar Therapeutics, and many more.
Offering a uniquely integrated view of challenges and opportunities defining the next decade of IPF drug development, from novel biology and biomarker-driven strategies to next-generation trial design and combination approaches, this is where leaders come to align on what success now looks like.
If you’re looking to stay competitive in a rapidly evolving field, this is the room you need to be in.
Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.net, which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.